Roots Analysis has announced theaddition of “Global Psychedelic Therapeutics Market, 2020-2030” report to its list of offerings.
The report features an extensive study of the currentmarket landscape, offering an informed opinion on the likely adoption of thesetherapies over the next decade. It features an in-depth analysis, highlightingthe capabilities of various stakeholders engaged in this domain. In addition toother elements, the study includes:
§ A detailed assessment of the current market landscape of drugdevelopers engaged in the development of psychedelic therapeutics.
§ Tabulated profiles of prominent psychedelic therapeuticsdevelopers. shortlisted on the basis of the number of pipeline products).
§ Detailed profiles of developers of next generation immunecheckpoint modulators (shortlisted on the basis having two or more psychedelics-basedtherapies in phase II clinical studies and above).
§ An insightful analysis of clinical trial sites where thestudies have been / are being conducted for evaluation of various psychedelictherapeutics.
§ A list of key opinion leaders (KOLs) within this domain,and detailed 2×2 matrices to assess the relative experience of key individualswho were shortlisted based on their contributions (in terms of involvement invarious clinical studies) to this field.
§ A detailed analysis of nearly 545 grants that have beenawarded to research institutes engaged in psychedelic therapeutics projects, inthe period between 2015 and 2020 (till May).
§ An analysis of the partnerships that have been establishedin the recent past (2017-2020 till May),
§ A detailed analysis of the various mergers and acquisitionsthat have taken place in this domain, highlighting the trend in the number ofcompanies acquired between 2017-2020.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ TargetDisease Indication
§ Anxiety and Depression
§ Trauma
§ Pain Disorder
§ Sleep related Disorder
§ Origin ofPsychedelic Substance
§ Natural
§ Synthetic
§ Type ofPsychedelic Substance
§ Gamma-hydroxybutyrate
§ Ketamine
§ MDMA
§ Psilocybin
§ Route ofAdministration
§ Oral
§ Intranasal
§ Sublingual
§ KeyGeographies
§ North America
§ Europe
§ Asia-Pacific
Transcripts of interviews heldwith the following senior level representatives of stakeholder companies
§ AndrewChadeayne (Founder & Chief Executive Officer, CaaMTech)
§ Janakan Krishnarajah (Chief Operating Officer and Chief MedicalOfficer, iX Biopharma)
§ Alexander Speiser (Chief Operating Officer, Orthogonal Thinker)
§ Tracy Cheung, (Chief Communications Officer, COMPASS Pathways)
Keycompanies covered in the report
§ Celon Pharma
§ iX Biopharma
§ MAPS Public Benefit
§ MindMed
§ Janssen Pharmaceuticals
§ Jazz Pharmaceutical
For additional details, pleasevisit
https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.htmloremail sales@rootsanalysis.com
You may also be interested in thefollowing titles:
1. Endocannabinoid SystemTargeted Therapeutics Market, 2020-2030
3. Alzheimer's Disease:Pipeline Review, Developer Landscape and Competitive Insights
4. Neoantigen TargetedTherapies Market, 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
